Can Amgen Advance On Anti-Obesity Drugs?
Amgen shows a historically strong seasonal pattern from June 30 to September 1, with a win rate of 76% over the past 25 years. The biotech giant is also advancing in the anti-obesity space, with its MariTide treatment in late-stage trials. Investors may see added upside potential as healthcare stocks gain favor in uncertain economic times.